Tolperisone, lidocaine (Myorizon) injections 100 mg/ml + 2.5 mg/ml 1 ml – [5 ampoules]

Description

Myorisone Pharmacodynamics
Tolperizone hydrochloride is a myorelaxant of central action. It has membrane stabilizing, local anesthetic effect, inhibits conduction of nerve impulses in primary afferent fibers and motor neurons, which leads to blocking of spinal mono- and polysynaptic reflexes. Presumably, tolperizone mediates the blocking of mediator release by inhibition of calcium ion entry into synapses. Inhibits the conduction of excitation along the reticulospinal pathway in the brainstem. Regardless of the effect on the central nervous system (CNS), it increases the peripheral blood supply. This effect is not related to the effect of the drug on the central nervous system and may be due to the weak antispasmodic and antiadrenergic effect of tolperizone.
Lidocaine hydrochloride has local anesthetic effect and has no systemic action when dosed according to the instructions.

Indications
Symptomatic treatment of stroke-related spasticity in adults. Moderate to severe myofascial pain syndrome (including muscle spasm in dorsopathies).

Contraindications
Hypersensitivity to tolperizone or chemically similar eperizone or to any of the drug components (including lidocaine);
myasthenia gravis;
childhood under 18 years of age;
pregnancy;
Breast-feeding period.
Caution
If you suffer from one of the above mentioned diseases, consult your physician before taking the drug.
The drug should be used with caution in women, patients with hypersensitivity to other drugs or with allergy in anamnesis (see section “Special indications”), patients with renal and hepatic insufficiency (see section “Dosage and administration”).
Administration during pregnancy and breastfeeding
Pregnancy
Teratogenic action of tolperizone has not been revealed in experimental studies on animals. For the lack of significant clinical data tolperizone should not be used during pregnancy, except in cases when the expected benefit to the mother exceeds the potential risk to the fetus.
Breastfeeding
As there are no data on excretion of tolperizone with breast milk, its use during breast-feeding is contraindicated.

Dosage and administration method

• Adults: 1 ml (100 mg tolperizone) 2 times per day intramuscularly or 1 ml (100 mg tolperizone) 1 time per day intravenously, slowly.
• Patients with renal impairment: experience of tolperizone administration in patients with renal impairment is limited, adverse reactions were more frequent in this category of patients. Therefore, in patients with moderate renal impairment the dose of tolperizone should be adjusted with close monitoring of the patient’s health status and renal function control. In patients with severe renal impairment, administration of tolperizone is not recommended.
• Patients with hepatic impairment: experience of tolperizone administration in patients with hepatic impairment is limited, this category of patients more often had adverse reactions. Therefore, in patients with moderate hepatic impairment the dose of tolperizone should be adjusted with close monitoring of the patient’s health status and liver function control. In severe hepatic impairment the prescription of tolperizone is not recommended.
• Administration in children
  The drug is not intended for use in children under 18 years of age.